Stifel lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $15 from $16 and keeps a Buy rating on the shares. The firm updated its model for the quarter, including the cash guidance, and made adjustments to near- to mid-term expense assumptions and the commercialization timeline given the prioritization of the first-line opportunity, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue